Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 63,309 shares, a growth of 294.1% from the November 30th total of 16,064 shares. Based on an average daily trading volume, of 287,693 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 287,693 shares, the short-interest ratio is currently 0.2 days.

Analysts Set New Price Targets

A number of brokerages recently commented on ALPMY. Sanford C. Bernstein downgraded Astellas Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 2nd. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Astellas Pharma currently has an average rating of “Hold”.

Astellas Pharma Stock Down 0.4%

ALPMY opened at $13.40 on Friday. The business has a 50 day moving average price of $12.14 and a two-hundred day moving average price of $11.07. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.80 and a current ratio of 1.03. Astellas Pharma has a 1-year low of $8.37 and a 1-year high of $13.92.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.10. The company had revenue of $3.45 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%. Research analysts anticipate that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).